Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of April 2026, specifically reporting transaction notifications for Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The filing serves as a regulatory disclosure of insider trading activity rather than a periodic financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to specific share transaction details:
- Transaction 1: Purchase of 4,000 Ordinary Shares at £19.6291 per share on April 29, 2026, on the London Stock Exchange.
- Transaction 2: Acquisition of 12.874 American Depositary Shares (ADS) at $54.5854 per share on April 27, 2026, on the New York Stock Exchange under the GSK pension plan.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses changes in share ownership by specific individuals.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It includes a standard corporate description stating GSK is a global biopharma company focused on uniting science, technology, and talent.
Investor Verification Checklist
- Verify the identity and role of Wendy Becker (Independent Non-Executive Director) regarding the purchase of 4,000 Ordinary Shares.
- Confirm the nature of Diana Conrad's (Chief People Officer) acquisition of 12.874 ADS as a pension plan transaction.
- Check the prevailing market price of GSK Ordinary Shares and ADS on April 27 and 29, 2026, to contextualize the transaction prices.
- Review subsequent filings for any amendments to these transaction notifications.